Natco Pharma Q3 net down 39% at ₹63 crore

Our Bureau Hyderabad | Updated on February 11, 2021

Total revenue too fell 24.7% to ₹386 crore compared to ₹513 crore in the same period last year

Natco Pharma Ltd said consolidated net profit had declined 39.4 per cent at ₹63.40 crore in the third quarter ended December 31, 2020 against ₹104 crore in the corresponding quarter of the previous financial year.

The total revenue of the Hyderabad-based company declined 24.7 per cent at ₹386 crore compared to ₹513 crore in the same period last year.

Also read: Natco Pharma expects agri business to be key growth lever

“The decline in revenue and profits was due to lower sales in domestic oncology and weak realisation of profits from Oseltamivir in the USA,” the company said in a release issued on Thursday.

The board of directors has recommended a third interim dividend of ₹1 per equity share of face value ₹2 each.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 11, 2021
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.